Abstract: Provided is a method for performing reconstruction and noise removal with high accuracy on various undersampling patterns including equidistant undersampling. An image processing unit that processes measurement data acquired by an MRI apparatus performs image reconstruction by using measurement data on respective channels measured in a predetermined undersampling pattern and sensitivity distributions of respective reception coils. At this time, denoising of a reconstructed image and a calculation for maintaining consistency between original measurement data and the measurement data on the respective channels created from denoised images are sequentially processed. Accordingly, image restoration and denoising with high accuracy are possible without depending on the undersampling pattern.

Abstract: Amusement game equipment supports a ride section on which a user rides by an air spring section, measures a height of a reference plane of the ride section with a sensor, and controls air supply and discharge into/from the air spring section according to game progress by a control section. The control section performs a calibration process for determining an ascent limit of the ride section based on a measured value by the sensor so as to set an ascent and descent control range excluding a predetermined margin from the ascent limit, and a target height setting process for setting a target height of the ride section within the ascent and descent control range according to the game progress, and controls the air supply and discharge into/from the air spring section to achieve the target height.

Abstract: A vehicle seat frame includes a seat cushion frame, left and right links, a connection member, left and right slide rails, and left and right risers. The seat cushion frame includes left and right side frames. The left and right links each have a one end portion connected to respective front portions of the left and right side frames. The connection member connects the left and right links together in the seat left-right direction. The left and right slide rails are disposed below the left and right side frames and are attached to a floor section of the vehicle. The left and right risers are respectively attached to the left and right slide rails, are connected to respective other end portions of the left and right links, and are configured to be impacted by the connection member under load from the occupant during a head-on collision of the vehicle.

Abstract: A CPAP system includes a CPAP device and a reception part. The CPAP device is capable of executing a determination process, a first transmission process, and a second transmission process. The determination process is a process in which a determination about whether a respiratory therapy with the CPAP device has been performed within a predetermined fixed period is made. The first transmission process is a process in which execution completion information is transmitted to the reception part in response to a determination in the determination process. The second transmission process is a process in which non-execution information is transmitted to the reception part in response to a determination in the determination process. The reception part is capable of executing a surmise process in which a non-therapy period in which the respiratory therapy has not been performed is surmised based on the execution completion information and the non-execution information.

Abstract: In a vehicle seat frame, a connection member that connects left and right links together in a seat left-right direction is disposed below a rear portion of a cushion pan included in a seat cushion frame. A sloped surface sloped with a downward gradient toward a seat rear side is formed at a lower surface of the rear portion of the cushion pan. The sloped surface of the cushion pan slides in a seat rearward and diagonally downward direction relative to the connection member when the cushion pan deforms in a seat downward direction under load from the occupant during a head-on collision of the vehicle.

Abstract: An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer. An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon ? by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.

Abstract: The present invention provides a polypeptide comprising a modified Fc region of an IgG, and a modified Fcy receptor that binds specifically to the polypeptide, and methods for treating or preventing a disease or a disorder in a patient using immunotherapy.

Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.

Abstract: Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.

Abstract: Provided is a conjugate comprising a ligand, a spacer, and a peptide linker useful for an in-vivo diagnostic drug and internal radiation therapy, using an anti-human CEACAM5 antibody Fab fragment whose binding activity is not attenuated even by labeling with a metal, a fluorescent dye, or the like. A conjugate comprising an anti-human CEACAM5 antibody Fab fragment and a ligand, the fragment comprising a heavy chain fragment including a heavy chain variable region consisting of a specific amino acid sequence and a light chain including a light chain variable region consisting of a specific amino acid sequence, or a conjugate comprising a ligand, a spacer, and a peptide linker, wherein the binding activity thereof is not attenuated even by labeling with a metal, a fluorescent dye, or the like, can be used as a diagnostic composition and/or a pharmaceutical composition.

Abstract: Provided are a conjugate comprising an anti-human MUC1 antibody Fab fragment and a peptide linker and/or a ligand, a composition for diagnosis and/or a pharmaceutical composition comprising the conjugate, a method for diagnosing and/or treating a cancer using the conjugate, and the like. In the conjugate used, the anti-human MUC1 antibody Fab fragment is bound to the ligand via the peptide linker or the like.

Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.

Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.

Abstract: Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.

Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.

Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.

Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.

Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.

Abstract: To provide a semiconductor device featuring reduced variation in capacitor characteristics. In the semiconductor device, a protective layer is provided at the periphery of the upper end portion of a recess (hole). This protective layer has a dielectric constant higher than that of an insulating layer placed in the same layer as the protective layer and configuring a multilayer wiring layer placed in a logic circuit region.

Abstract: A semiconductor device has a substrate; a multi-layered interconnect formed on the substrate, and having a plurality of interconnect layers, each of which being configured by an interconnect and an insulating layer, stacked therein; a memory circuit formed in a memory circuit region on the substrate in a plan view, and having a peripheral circuit and at least one capacitor element embedded in the multi-layered interconnect; and a logic circuit formed in a logic circuit region on the substrate, wherein the capacitor element is configured by a lower electrode, a capacitor insulating film, an upper electrode, an embedded electrode and an upper interconnect; the top surface of the upper interconnect, and the top surface of the interconnect configuring the logic circuit formed in the same interconnect layer with the upper interconnect, are aligned to the same plane.